Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Sellas - that deal included 0 upfront and up to 350-400 in milestones, but look at the company's markrt cap. I wouldn't hold my breath waiting on any money from them, similar to O'Connor's Asia and India deals. Also milestones are contingent payments based on future events. ADXS has already dragged it feet more than a year on starting NEO, while ADRO just announced prelim data on their. The story of ADXS is poor execution with no sense of urgency except for when it comes to management compensation.